Generic Esbriet ( Pirfenidone )

Order cheap Generic Esbriet (Pirfenidone) without dr prescription in the United States

In our USA pharmacy, you can buy Esbriet without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Esbriet (pirfenidone) is an oral antifibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and stiffening of lung tissue. It works by inhibiting transforming growth factor‑beta (TGF‑β) and tumor necrosis factor‑alpha (TNF‑α), reducing the production of collagen and other fibrotic mediators, thereby slowing the decline in lung function.
Usual adult dose: Titration schedule: Days 1‑7: 200 mg three times daily (total 600 mg/day); Days 8‑14: 400 mg three times daily (total 1200 mg/day); Day 15 onward: 600 mg three times daily (total 1800 mg/day) as maintenance. The dose should be taken with food to improve tolerability.
Dosage form: Capsules (200 mg) and tablets (400 mg).
Onset of action: Clinical benefit (slowing of forced vital capacity decline) is observed over months; the full therapeutic effect may take up to 12 months of continuous therapy.
Duration of action: The antifibrotic effect persists while on maintenance therapy; discontinuation leads to loss of benefit.
Alcohol consumption should be limited or avoided; heavy alcohol intake may increase the risk of liver toxicity and may worsen gastrointestinal side effects.
Most common side effects: nausea, rash, diarrhea, dyspepsia, vomiting, fatigue, upper respiratory tract infection, and photosensitivity (increased sun sensitivity).
Would you like to try Esbriet without a prescription?

General Information about Esbriet

• INN (International Nonproprietary Name): Pirfenidone
• Brand names available in the USA: Esbriet® (Genentech, Inc.). Generic pirfenidone tablets/capsules are manufactured by Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., and other FDA‑approved generic manufacturers.
• ATC code: L04AX05
• Dosage forms and strengths: Oral capsules containing 200 mg of pirfenidone; oral tablets containing 400 mg of pirfenidone.
• Manufacturers in USA: Genentech, Inc. (brand Esbriet®); generic manufacturers include Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., and others.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on October 15, 2014 (NDA 022535).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Pirfenidone is a pyridone derivative with broad‑spectrum anti‑inflammatory and antifibrotic properties. Although its exact mechanism of action is not fully understood, it is known to inhibit the synthesis of transforming growth factor‑beta (TGF‑β) and tumor necrosis factor‑alpha (TNF‑α), two key cytokines that drive fibroblast proliferation, myofibroblast differentiation, and extracellular matrix deposition. By attenuating these pathways, pirfenidone reduces collagen production and fibrotic tissue formation, thereby slowing the progression of lung fibrosis in IPF. Pirfenidone also possesses antioxidant activity through free radical scavenging. Following oral administration, it is rapidly absorbed; bioavailability is significantly increased when taken with food, which also reduces gastrointestinal side effects. Peak plasma concentrations are reached within 0.5‑3 hours. Pirfenidone is metabolized primarily in the liver via CYP1A2, with minor contributions from other CYP isoforms. The elimination half‑life is approximately 2.5 hours. Excretion is predominantly renal, with over 80% of the dose recovered in urine as metabolites and unchanged drug.

Indications

• Treatment of idiopathic pulmonary fibrosis (IPF) in adults to slow the decline of forced vital capacity (FVC).
• There are no other FDA‑approved indications; off‑label use in other fibrotic lung diseases is being investigated.

Important Warnings and Precautions

Esbriet (pirfenidone) has been associated with elevations in hepatic transaminases; liver function tests (ALT, AST, and bilirubin) must be measured before initiation, monthly for the first 6 months, and then every 3 months thereafter. Dose reduction or permanent discontinuation may be necessary if liver enzymes are persistently elevated. Severe photosensitivity reactions, including sunburn and phototoxic rash, are common; patients must avoid direct sun exposure, use broad‑spectrum sunscreens, and wear protective clothing. Rash is a frequent side effect and may be managed with topical therapies; severe or persistent rash may require dose adjustment. Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) are very common and can be mitigated by taking the medication with food. Dizziness and fatigue have been reported; caution is advised when driving or operating machinery. Pirfenidone has been associated with angioedema and severe hypersensitivity reactions; discontinue immediately if these occur. The safety and efficacy of pirfenidone have not been established in patients with severe hepatic impairment or end‑stage renal disease requiring dialysis.

At‑risk groups

• Elderly: No dose adjustment is required based solely on age; however, the majority of IPF patients are elderly, and hepatic function should be monitored closely.
• Pregnancy: There are no adequate and well‑controlled studies in pregnant women. Based on animal data, pirfenidone may cause fetal harm. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding: It is not known whether pirfenidone is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. A decision should be made whether to discontinue nursing or the drug.
• Renal impairment: No dose adjustment is required for mild to moderate renal impairment. Use with caution in patients with severe renal impairment (creatinine clearance
• Hepatic impairment: Pirfenidone should not be used in patients with severe hepatic impairment or end‑stage liver disease. In patients with mild to moderate hepatic impairment (Child‑Pugh A or B), no initial dose adjustment is required, but close monitoring of liver function is mandatory. Discontinue if significant hepatic dysfunction develops.
• Pediatric: Safety and efficacy have not been established in pediatric patients.
• Smokers: Smoking induces CYP1A2 and may reduce pirfenidone exposure; patients should be strongly encouraged to stop smoking before and during therapy.

Driving and alcohol

Pirfenidone may cause dizziness, fatigue, and somnolence, which can impair the ability to drive or operate machinery. Patients should avoid driving or engaging in hazardous activities until they know how the medication affects them. Alcohol consumption should be limited or avoided. Heavy alcohol intake may increase the risk of hepatotoxicity and exacerbate gastrointestinal side effects. In combination with pirfenidone, alcohol may also potentiate dizziness and drowsiness.

Dosage Instructions

• Titration schedule: To improve gastrointestinal tolerability, pirfenidone is initiated at a low dose and gradually increased:
  • Days 1‑7: 200 mg orally three times daily (total 600 mg/day).
  • Days 8‑14: 400 mg orally three times daily (total 1200 mg/day).
  • Day 15 onward: 600 mg orally three times daily (total 1800 mg/day).
• Maintenance dose: 600 mg three times daily (1800 mg/day). The maximum recommended daily dose is 2400 mg/day; some international guidelines allow up to 2400 mg/day in divided doses, but the FDA‑approved target is 1800 mg/day.
• Administration: Take each dose with a meal or snack to reduce nausea and diarrhea. Swallow capsules/tablets whole with a full glass of water. Do not crush, chew, or break them. If a dose is missed, take the next dose at the regular time; do not double the dose.
• Dose adjustments for adverse events: For intolerance (e.g., severe rash, persistent GI symptoms), the dose may be reduced to 400 mg three times daily or temporarily interrupted. Re‑escalation to the target dose may be attempted after symptoms resolve. For liver enzyme elevations: if ALT or AST >3 to 5× upper limit of normal (ULN), reduce the dose or interrupt; if >5× ULN or accompanied by jaundice, permanently discontinue.
• Renal or hepatic impairment: Mild to moderate impairment requires no initial adjustment but mandates close monitoring. Do not use in severe hepatic impairment.
• Smoking cessation: Strongly encourage smoking cessation, as smoking reduces pirfenidone exposure and may lessen efficacy.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥10%): Nausea (36%), rash (30%), diarrhea (26%), fatigue (26%), dyspepsia (19%), vomiting (13%), headache (12%), and upper respiratory tract infection (11%). Photosensitivity reactions (sunburn‑like rash) are very common (up to 50%). Gastrointestinal side effects are most prominent during the first few weeks and may improve with dose titration and food intake.
Other clinically important adverse reactions: Elevations in liver transaminases (ALT, AST) occurring in 3‑5% of patients; generally reversible with dose reduction or discontinuation. Dizziness, weight loss, decreased appetite, and taste disturbance have also been reported.
Serious adverse reactions: Severe hepatic injury (rare, but cases of acute liver failure have been reported post‑marketing); angioedema; severe phototoxic rash requiring hospitalization; and thrombocytopenia.
Absolute contraindications: Known hypersensitivity to pirfenidone or any excipient; concomitant use with fluvoxamine (strong CYP1A2 inhibitor that significantly increases pirfenidone exposure and toxicity risk).

Drug Interactions

• Fluvoxamine: A strong CYP1A2 inhibitor; concurrent use is contraindicated because it dramatically increases pirfenidone exposure and the risk of serious adverse events. Avoid other strong CYP1A2 inhibitors such as ciprofloxacin (used with caution; dose reduction of pirfenidone may be needed).
• Moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin): May increase pirfenidone levels; consider a temporary dose reduction of pirfenidone to 200 mg three times daily when ciprofloxacin is used for a short course. If ciprofloxacin is taken for an extended period, reduce pirfenidone to 400 mg three times daily. Monitor for adverse effects.
• Strong CYP1A2 inducers (e.g., rifampin, omeprazole in high doses, tobacco smoking): May significantly reduce pirfenidone exposure, potentially decreasing efficacy. Avoid concomitant use of rifampin; smoking cessation is critical to maintain therapeutic levels.
• Other CYP1A2 substrates (e.g., theophylline): Pirfenidone may alter the metabolism of theophylline; monitor theophylline levels when initiating or discontinuing pirfenidone.
• Grapefruit juice and seville oranges: Moderate CYP1A2 inhibitors; concurrent consumption may increase pirfenidone levels. Limit or avoid large quantities of grapefruit juice during therapy.
• Alcohol: Heavy alcohol intake may increase hepatotoxicity risk; limit or avoid.
• Pirfenidone does not significantly inhibit or induce other CYP enzymes; no clinically relevant interactions with warfarin, digoxin, or hormonal contraceptives have been observed.

Practical Advice

• Take Esbriet exactly as prescribed with a meal or snack. This reduces nausea and diarrhea and increases absorption.
• Do not stop taking Esbriet abruptly without consulting your healthcare provider. Interruption may be necessary for managing side effects, but the goal is to maintain continuous therapy to slow lung function decline.
• If you miss a dose, skip it and take the next dose at the regular time. Do not take two doses at once to make up for a missed one.
• Use protective measures to avoid sun exposure: apply a broad‑spectrum sunscreen (SPF 50+), wear long‑sleeved clothing, a wide‑brimmed hat, and sunglasses. Avoid tanning beds and prolonged sun exposure, even on cloudy days.
• Report any rash, even mild, to your healthcare provider; early management may prevent progression to severe phototoxicity.
• Inform your healthcare provider immediately if you experience signs of liver problems: yellowing of the skin or eyes (jaundice), dark urine, light‑colored stools, severe nausea or vomiting, unexplained fatigue, or right upper abdominal pain.
• Avoid grapefruit juice, seville oranges, and their products during therapy, as they may increase blood levels of pirfenidone.
• If you smoke, quit. Smoking significantly reduces the effectiveness of pirfenidone. Your healthcare provider can assist with smoking cessation resources.
• Regular liver function tests (ALT, AST, bilirubin) will be ordered: before starting, monthly for the first 6 months, and then every 3 months. Keep all laboratory appointments.
• Store at room temperature (20‑25°C / 68‑77°F) in the original container, protected from light and moisture. Keep out of reach of children.
• Never share this medication with anyone else; it is prescribed specifically for your condition based on a confirmed diagnosis of IPF.

Alternative Medications

• Nintedanib (Ofev®): An oral tyrosine kinase inhibitor that also slows the decline of FVC in IPF. It is dosed twice daily and has a different side‑effect profile (diarrhea, nausea, liver enzyme elevation). Nintedanib and pirfenidone are the only two FDA‑approved disease‑modifying therapies for IPF.
• Lung transplantation: The only definitive treatment for advanced IPF; antifibrotic therapy may be used as a bridge to transplant.
• Supportive care: Supplemental oxygen, pulmonary rehabilitation, and vaccination against influenza and pneumococcus are essential components of IPF management.
• There are no other FDA‑approved pharmacologic alternatives; previous treatments such as corticosteroids, azathioprine, and N‑acetylcysteine are not recommended due to lack of benefit or potential harm.

Clinical Efficacy

The efficacy of pirfenidone in IPF was demonstrated in three phase 3, randomized, double‑blind, placebo‑controlled trials (ASCEND and CAPACITY studies). In the ASCEND trial, pirfenidone reduced the decline in percent predicted forced vital capacity (FVC) at week 52 by 47.9% compared with placebo (mean absolute change of ‑235 mL vs. ‑428 mL; p<0.001). A significant reduction in the proportion of patients with a ≥10% decline in FVC or death (primary endpoint) was also observed. Pooled analysis of all three pivotal trials showed a 43.8% reduction in the risk of all‑cause mortality over 1 year (p=0.01). Treatment with pirfenidone also reduced the rate of respiratory hospitalization and delayed disease progression as measured by the 6‑minute walk distance. Long‑term extension studies have shown that the benefit on lung function decline is maintained over several years, with a manageable safety profile. Pirfenidone is currently recommended by international guidelines (ATS/ERS/JRS/ALAT) as a conditional recommendation for the treatment of IPF.

Important:

Esbriet (pirfenidone) is a prescription antifibrotic medication that must be used under the supervision of a healthcare provider experienced in the management of idiopathic pulmonary fibrosis. Liver function must be monitored regularly; failure to do so can result in unrecognized severe hepatic injury. This drug causes severe photosensitivity; patients must avoid direct sun exposure, tanning beds, and use daily high‑SPF sunscreens and protective clothing. Gastrointestinal side effects (nausea, vomiting, diarrhea) are very common and are best managed by taking the medication with food and following the dose titration schedule. Smoking must be avoided entirely, as it reduces the effectiveness of the drug. Do not stop taking Esbriet without consulting your physician; interruption of therapy may lead to loss of the beneficial effect on lung function. Concomitant use of fluvoxamine is contraindicated, and ciprofloxacin should be used with caution. Women who are pregnant or planning to become pregnant should discuss the potential risks with their doctor; effective contraception is required during treatment. Keep out of reach of children and never share this medication with others. If you experience jaundice, severe rash, angioedema, or persistent vomiting, seek immediate medical attention.

How to buy Generic Esbriet no prescription U.S. Online Pharmacy